Phase 2 Relapsed Non Hodgkin Lymphoma Clinical Trials
10 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 2
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Large B-cell LymphomaRelapsed Non Hodgkin Lymphoma
H. Lee Moffitt Cancer Center and Research Institute27 enrolled1 locationNCT06104592
Recruiting
Phase 2
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Refractory Non-Hodgkin LymphomaB-cell LymphomaRelapsed Non Hodgkin Lymphoma+2 more
Rita Assi24 enrolled2 locationsNCT06484920
Recruiting
Phase 1Phase 2
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Relapsed Pediatric ALLRelapsed Non Hodgkin LymphomaRelapsed Adult ALL
University of Alberta63 enrolled6 locationsNCT03938987
Recruiting
Phase 2
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
Lazaros Lekakis22 enrolled1 locationNCT05260957
Recruiting
Phase 2
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+4 more
Marcela V. Maus, M.D.,Ph.D.28 enrolled2 locationsNCT06550141
Recruiting
Phase 1Phase 2
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
High-grade B-cell LymphomaNon-Hodgkin LymphomaLymphoma+12 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1Phase 2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+4 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Phase 2
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Follicular LymphomaRelapsed Non Hodgkin LymphomaRefractory B-Cell Lymphoma
The First Affiliated Hospital of Xiamen University33 enrolled1 locationNCT06158386